Neuropeptide W-23 (human) NPW-23|cas:383415-79-0|西域试剂

Neuropeptide W-23 (human) NPW-23

产品编号：Bellancom-P1035| CAS NO：383415-79-0| 分子式：C₁₁₉H₁₈₃N₃₅O₂₈S| 分子量：2584.01

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P1035		￥2200.00	杭州北京（现货）
Bellancom-P1035		￥9900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Neuropeptide W-23 (human) NPW-23

产品介绍

Neuropeptide W-23 (human) (NPW-23) 是 Neuropeptide W 的主要活性形式，为 NPBW1 (GPR7) 和 NPBW2 (GPR8) 的内源性激动剂。

生物活性

Neuropeptide W-23 (human) (NPW-23), the active form of Neuropeptide W, is an endogenous agonist of NPBW1 (GPR7) and NPBW2 (GPR8).

体外研究

Neuropeptide W-23 (human) (NPW-23) increases the I_Ca,L in transfected human embryonic kidney 293 cells and VSMCs via GPR7.
Neuropeptide W-23 (human) increases the expression of pan phospho-PKC, intracellular diacylglycerol level, and the second messenger catalyzed by PLC.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Neuropeptide W-23 (human) (NPW-23) (0.3-3.0 nM; intracerebroventricular injection; 2 μL) increases total behavioral activity, including locomotion and grooming in conscious rats.
Neuropeptide W-23 (human) (NPW-23) (2-8 nM; i.c.v.; 10 μL) shows anorexigenic effect in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Harlan Sprague-Dawley rats, 250–300 g
Dosage:	0.3, 1.0 and 3.0 nM
Administration:	Intracerebroventricular injection, 2 μL
Result:	Caused significant increases in mean arterial pressure. Demonstrated a significant increase in total activity, ambulatory activity, and duration of stereotypy.

Animal Model:	Male Wistar rats weighing 250–300 g
Dosage:	2, 4, 6 and 8 nM
Administration:	Intra-cerebroventricular injection, 10 μL
Result:	Decreased dark feeding and fasting-induced feeding, decreased feeding intake and weight gain.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Harlan Sprague-Dawley rats, 250–300 g
Dosage:	0.3, 1.0 and 3.0 nM
Administration:	Intracerebroventricular injection, 2 μL
Result:	Caused significant increases in mean arterial pressure. Demonstrated a significant increase in total activity, ambulatory activity, and duration of stereotypy.

Animal Model:	Male Wistar rats weighing 250–300 g
Dosage:	2, 4, 6 and 8 nM
Administration:	Intra-cerebroventricular injection, 10 μL
Result:	Decreased dark feeding and fasting-induced feeding, decreased feeding intake and weight gain.